People

RICKY SIEWERS

Ricky Siewers began his career at Bloomberg LP as a specialist for the Bloomberg Terminal, the preeminent financial software tool that connects decision makers to a network of information, people, and ideas. In his time at Bloomberg, he has specialized in providing Terminal solutions for financial professionals across multiple asset classes and portfolio tools. Ricky currently provides consultative solutions for key account asset managers to optimize their investment process and develops strategies to further drive business on an enterprise level. Ricky also has prior experience in product marketing through the Harvard Innovation Lab’s Venture Incubation Program.

Ricky graduated from the Virginia Military Institute with a degree in Business & Economics.

JANET CHECKMAN

Janet Checkman is Director of Business Development & Marketing for Jeffrey Berman Architect. She has 30 years of experience in communications, business development and marketing for design, healthcare, finance and entertainment organizations. She earned her B.A. from the University of California, Berkeley and her M.A. from Columbia University.

Ms. Checkman has worked for a diverse list of clients that includes NYU Langone Medical Center, Filmways, Inc. and the Charles Eames Office and has developed business with most of the major hospitals in the New York City area.

Ms. Checkman has worked with Jeffrey Berman Architect for the last 8 years. She has been affiliated with the Association of Real Estate Women, Health Leaders of New York/ACHE, the Society for Design Administration and the Society for Marketing Professionals Services.

MICHAEL KELLICK, BS/MS PHARM, PHARMD

Dr. Michael Kellick has over 43 years of experience in Pediatric Hematology/Oncology Pharmacy with extensive patient care work and on both institutional and Cooperative Group research efforts. Dr. Kellick has been a co-investigator on numerous clinical trials. Dr. Kellick has retired in 2018 from Memorial Sloan Kettering Cancer Center where he served as the Clinical Coordinator for Pediatric Pharmacy Practice.

He has served as the lead pharmacist for the Pediatric Oncology Experimental Therapeutic Investigators Consortium (POETIC). He has also served as Chair of the CCG Pharmacy Committee and Vice Chair of the COG Pharmacy Committee. Dr. Kellick has made significant contributions to the Children’s Oncology group having served as lead writer of the CCG and subsequently the COG Pharmacy Committee’s Protocol Review Guidelines and as a Co-author of the COG Chemotherapy Administration Guidelines.

Although retired, currently, Dr. Kellick is a board member of the National Cancer Institute’s Central Institutional Review Board (CIRB) since 2012. He reviews treatment protocols for the Children’s Oncology Group, Pediatric Brain Tumor Consortium and the Pediatric Cancer Immunotherapy Trials Network. He is also a volunteer in the development of the International Childrens Cancer Research Center, to be built in Ghana.

Dr. Kellick holds the following professional degrees: Bachelor of Science degree in Pharmacy from the State University of Buffalo; Master of Science degree in Pharmacy from St John’s University and Doctor of Pharmacy from the University of Florida.Dr. Michael Kellick has over 43 years of experience in Pediatric Hematology/Oncology Pharmacy with extensive patient care work and on both institutional and Cooperative Group research efforts. Dr. Kellick has been a co-investigator on numerous clinical trials. Dr. Kellick has retired in 2018 from Memorial Sloan Kettering Cancer Center where he served as the Clinical Coordinator for Pediatric Pharmacy Practice.

He has served as the lead pharmacist for the Pediatric Oncology Experimental Therapeutic Investigators Consortium (POETIC). He has also served as Chair of the CCG Pharmacy Committee and Vice Chair of the COG Pharmacy Committee. Dr. Kellick has made significant contributions to the Children’s Oncology group having served as lead writer of the CCG and subsequently the COG Pharmacy Committee’s Protocol Review Guidelines and as a Co-author of the COG Chemotherapy Administration Guidelines.

Although retired, currently, Dr. Kellick is a board member of the National Cancer Institute’s Central Institutional Review Board (CIRB) since 2012. He reviews treatment protocols for the Children’s Oncology Group, Pediatric Brain Tumor Consortium and the Pediatric Cancer Immunotherapy Trials Network. He is also a volunteer in the development of the International Childrens Cancer Research Center, to be built in Ghana.

Dr. Kellick holds the following professional degrees: Bachelor of Science degree in Pharmacy from the State University of Buffalo; Master of Science degree in Pharmacy from St John’s University and Doctor of Pharmacy from the University of Florida.

LORAN KORANTENG

NANA MENSAH